MAP2K7 and cancer: (A) Increased lethality in patients due to cardiovascular (CV) risk factors with different types of cancer, a follow-up to 120 months after the cancer diagnosis, cohort of approximately 140,000 patients, data adapted from [14] (B) Cardiac abnormalities caused by chemotherapy such as cytostatic agents, tyrosine kinases inhibitors (including EGFR inhibitors), VEGF and MEK/BRAF inhibitors, immune-checkpoint inhibitors and proteasome inhibitors adapted from [10].